Compare Diamondback Energy Inc (FANG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Diamondback Energy Inc trades at $193.08 (market cap $53.67B), while Vertex Pharmaceuticals Incorporated trades at $509.61 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.4× Diamondback Energy Inc's market cap, and Diamondback Energy Inc pays a 2.3% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FANG | VRTX | |
|---|---|---|
Market Cap | $53.67B | $127.55B |
Volume | 2,250,644 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $213.69 | $557.96 |
52-Week Low | $137.29 | $407.37 |
Typical Hold Time | 69 Days | 120 Days |
Enterprise Value | $65.83B | $121.68B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $184.38, down 0.32% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth from $14.93B in 2025 to projected $17.0B in 2026, though net margins have compressed. Recent Q2 2026 earnings beat expectations at $6.48 EPS versus $6.08 expected. Analyst sentiment remains overwhelmingly positive with 90.57% buy ratings and a $231.77 consensus price target, representing 26% upside from current levels.
FANG presents a compelling growth story with robust cash flow generation and strategic positioning in the Permian Basin. Key risks include oil price volatility and insider selling activity. The stock's current valuation at 36.51 P/E appears reasonable given growth prospects, while technical support at $182 provides a near-term floor. Institutional accumulation and strong analyst support suggest confidence in long-term value creation.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
